bioAffinity Technologies, Inc. shared a patient case study on July 29, 2025, in which its CyPath® Lung test detected pulmonary mucinous adenocarcinoma at Stage 1A. This occurred in a high-risk patient whose previous tests, including PET scans and blood-based risk tests, had indicated a low probability of cancer.
The patient, a 62-year-old with a history of heavy smoking and COPD, had a suspicious ground-glass opacity on a CT scan. Despite low PET uptake and a low serum marker risk of 11%, a CyPath® Lung test result of 0.56, classified as 'likely malignancy,' prompted surgical consultation.
The patient subsequently underwent a wedge resection, and final pathology confirmed Stage 1A invasive mucinous adenocarcinoma, a lung cancer subtype often missed by standard imaging. This case underscores CyPath® Lung's ability to provide critical diagnostic clarity, preventing delayed diagnosis and enabling curative surgery for challenging cancer types.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.